AP Biosciences (6945) Stock Overview
Researches and develops protein and antibody drugs for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6945 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AP Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$190.50 |
| 52 Week High | NT$236.00 |
| 52 Week Low | NT$45.25 |
| Beta | -0.0063 |
| 1 Month Change | -7.75% |
| 3 Month Change | 13.06% |
| 1 Year Change | 302.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 142.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6945 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.3% | -2.1% | 5.4% |
| 1Y | 302.7% | 22.4% | 94.8% |
Return vs Industry: 6945 exceeded the TW Biotechs industry which returned 22.4% over the past year.
Return vs Market: 6945 exceeded the TW Market which returned 94.8% over the past year.
Price Volatility
| 6945 volatility | |
|---|---|
| 6945 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in TW Market | 12.0% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6945's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6945's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Jeng-Horng Her | www.apbioinc.com |
AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. It caters to healthcare and biotechnology industries.
AP Biosciences, Inc. Fundamentals Summary
| 6945 fundamental statistics | |
|---|---|
| Market cap | NT$16.30b |
| Earnings (TTM) | -NT$444.77m |
| Revenue (TTM) | n/a |
Is 6945 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6945 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$444.77m |
| Earnings | -NT$444.77m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6945 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 22:01 |
| End of Day Share Price | 2026/04/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AP Biosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.